Why the study?
Adrenocortical carcinoma carries a poor prognosis and is commonly misclassified when arising near the renal-adrenal interface, particularly in cases with vascular invasion.
This case highlights the critical need for routine preoperative hormonal screening in patients with large adrenal-adjacent masses to prevent misclassification and optimize perioperative management of adrenocortical carcinoma.
Adrenocortical carcinoma (ACC) is an endocrine malignancy with a poor prognosis due to its advanced stage at diagnosis and early metastatic potential. Misclassification is common when tumors arise near the renal-adrenal interface, particularly in cases with vascular invasion. We describe the case of a patient with a large retroperitoneal mass extending into the inferior vena cava whose initial imaging suggested a renal origin, resulting in deferred hormonal evaluation. Postoperative pathology confirmed ACC, and subsequent endocrine testing was consistent with a nonfunctional tumor. This case reinforces the need for improved guidelines and increased education, accounting for the variable presentations of ACC, to enhance diagnostic accuracy and optimize pre- and perioperative planning. As such, in cases of patients presenting with masses in the adrenal-adjacent regions, an endocrine workup of cortisol, androgens/estrogens, and mineralocorticoids should be the standard of care to rule out aggressive tumors such as ACC.
No takes yet. Share an insight, caveat, or question.
Kallarackal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: